adenine has been researched along with Head and Neck Neoplasms in 18 studies
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We tested 17 malignant mucosal melanomas of the head and neck for the thymine (T)-->adenine (A) missense mutation at nucleotide 1796 in the BRAF gene using direct sequencing and a newly developed assay that uses a novel primer extension method (Mutector assay)." | 3.72 | Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. ( Begum, S; Cohen, Y; Esche, C; Goldenberg, D; Lavie, O; Rosenbaum, E; Sidransky, D; Westra, WH, 2004) |
| "Further use in head and neck cancer appears unwarranted." | 2.68 | Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study. ( Benson, AB; Blough, R; French, S; Kies, M; Kilton, LJ; Lad, T; Mullane, M; Rosen, F; Vokes, EE; Wade, J, 1995) |
| "The current study tested the anti-HNSCC cell activity by a mTOR kinase inhibitor CZ415." | 1.48 | Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells. ( Ding, X; Gao, Y; Li, Q; Xie, J, 2018) |
| " Furthermore, it also demonstrates the benefits of using preclinical models of chemosensitization to radiotherapy to explore clinically relevant radiation dosing schemes." | 1.36 | BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. ( Burrows, F; Lundgren, K; Shores, CG; Wilson, L; Yin, X; Zhang, H, 2010) |
| "Microsatellite instability was detected in nine cases in both procedures." | 1.34 | Shorter CAG repeat length in the AR gene is associated with poor outcome in head and neck cancer. ( Canevari, Rde A; dos Santos, RM; Kowalski, LP; Magrin, J; Nishimoto, IN; Poli-Frederico, RC; Rainho, CA; Rogatto, SR; Rosa, FE, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Shan, L | 1 |
| Lu, Y | 1 |
| Song, Y | 1 |
| Zhu, X | 1 |
| Xiang, CC | 1 |
| Zuo, ED | 1 |
| Cheng, X | 1 |
| Jeske, SS | 1 |
| Brand, M | 1 |
| Ziebart, A | 1 |
| Laban, S | 1 |
| Doescher, J | 1 |
| Greve, J | 1 |
| Jackson, EK | 1 |
| Hoffmann, TK | 1 |
| Brunner, C | 1 |
| Schuler, PJ | 1 |
| Shin, D | 1 |
| Kim, EH | 1 |
| Lee, J | 1 |
| Roh, JL | 1 |
| Xie, J | 1 |
| Li, Q | 1 |
| Ding, X | 1 |
| Gao, Y | 1 |
| Soares, AC | 1 |
| Soares, JC | 1 |
| Rodrigues, VC | 1 |
| Follmann, HDM | 1 |
| Arantes, LMRB | 1 |
| Carvalho, AC | 1 |
| Melendez, ME | 1 |
| Fregnani, JHTG | 1 |
| Reis, RM | 1 |
| Carvalho, AL | 1 |
| Oliveira, ON | 1 |
| Behbahani, TE | 1 |
| Rosenthal, EL | 1 |
| Parker, WB | 1 |
| Sorscher, EJ | 1 |
| Khlifi, R | 1 |
| Kallel, I | 1 |
| Hammami, B | 1 |
| Hamza-Chaffai, A | 1 |
| Rebai, A | 1 |
| Niu, Y | 1 |
| Yuan, H | 1 |
| Shen, M | 1 |
| Li, H | 1 |
| Hu, Y | 1 |
| Chen, N | 1 |
| Schramm, VL | 1 |
| Gutierrez, JA | 1 |
| Cordovano, G | 1 |
| Basu, I | 1 |
| Guha, C | 1 |
| Belbin, TJ | 1 |
| Evans, GB | 1 |
| Tyler, PC | 1 |
| Furneaux, RH | 1 |
| Yin, X | 1 |
| Zhang, H | 1 |
| Lundgren, K | 1 |
| Wilson, L | 1 |
| Burrows, F | 1 |
| Shores, CG | 1 |
| Sharma, R | 1 |
| Panda, NK | 1 |
| Khullar, M | 1 |
| Cohen, Y | 2 |
| Xing, M | 1 |
| Mambo, E | 1 |
| Guo, Z | 1 |
| Wu, G | 1 |
| Trink, B | 1 |
| Beller, U | 1 |
| Westra, WH | 2 |
| Ladenson, PW | 1 |
| Sidransky, D | 3 |
| Rosenbaum, E | 1 |
| Begum, S | 1 |
| Goldenberg, D | 1 |
| Esche, C | 1 |
| Lavie, O | 1 |
| Boccia, S | 1 |
| Cadoni, G | 1 |
| La Torre, G | 1 |
| Arzani, D | 1 |
| Volante, M | 1 |
| Cattel, C | 1 |
| Gianfagna, F | 1 |
| Paludetti, G | 1 |
| Almadori, G | 1 |
| Ricciardi, G | 1 |
| Rosa, FE | 1 |
| dos Santos, RM | 1 |
| Poli-Frederico, RC | 1 |
| Canevari, Rde A | 1 |
| Nishimoto, IN | 1 |
| Magrin, J | 1 |
| Rainho, CA | 1 |
| Kowalski, LP | 1 |
| Rogatto, SR | 1 |
| Rosen, F | 1 |
| Vokes, EE | 1 |
| Lad, T | 1 |
| Kies, M | 1 |
| Wade, J | 1 |
| Kilton, LJ | 1 |
| Blough, R | 1 |
| French, S | 1 |
| Mullane, M | 1 |
| Benson, AB | 1 |
| Leaf, AN | 1 |
| Neuberg, D | 1 |
| Schwartz, EL | 1 |
| Wadler, S | 1 |
| Ritch, PS | 1 |
| Dutcher, JP | 1 |
| Adams, GL | 1 |
| Fisher, MJ | 1 |
| Virmani, AK | 1 |
| Wu, L | 1 |
| Aplenc, R | 1 |
| Harper, JC | 1 |
| Powell, SM | 1 |
| Rebbeck, TR | 1 |
| Gazdar, AF | 1 |
| El-Deiry, WS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors With Biologic and Proteomic Analysis[NCT00095459] | Phase 1 | 57 participants (Actual) | Interventional | 2004-11-02 | Completed | ||
| A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer[NCT00436215] | Phase 2 | 55 participants (Actual) | Interventional | 2006-12-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00436215)
Timeframe: up to 28 months
| Intervention | Participants (Count of Participants) |
|---|---|
| BAY 43-9006 + Bevacizumab | 54 |
Progression free survival is defined by the number of weeks between the first day of treatment and the date of cancer progression. (NCT00436215)
Timeframe: up to 28 months
| Intervention | Weeks (Mean) |
|---|---|
| BAY 43-9006 + Bevacizumab | 26 |
Clinical response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease (PD) is a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started lasting at least 6 months. (NCT00436215)
Timeframe: patients were followed for a median of 18 weeks (range 1-116 weeks)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| BAY 43-9006 + Bevacizumab | 0 | 19 | 21 | 60 |
1 review available for adenine and Head and Neck Neoplasms
| Article | Year |
|---|---|
Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck.
Topics: Adenine; Escherichia coli; Head and Neck Neoplasms; Humans; Purine-Nucleoside Phosphorylase; Squamou | 2019 |
2 trials available for adenine and Head and Neck Neoplasms
| Article | Year |
|---|---|
Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center study.
Topics: Adenine; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Hum | 1995 |
An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
Topics: Adenine; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head | 1997 |
15 other studies available for adenine and Head and Neck Neoplasms
| Article | Year |
|---|---|
Identification of Nine M6A-Related Long Noncoding RNAs as Prognostic Signatures Associated with Oxidative Stress in Oral Cancer Based on Data from The Cancer Genome Atlas.
Topics: Adenine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Gene Expression Regulation, Neoplastic; Head a | 2022 |
Adenosine-producing regulatory B cells in head and neck cancer.
Topics: Adenine; Adenosine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; B-Lymphocytes, Regulato | 2020 |
RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Topics: Adenine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2017 |
Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Topics: Adenine; Animals; Apoptosis; Autophagy; Beclin-1; Carcinoma, Squamous Cell; Cell Proliferation; Cell | 2018 |
Microfluidic-Based Genosensor To Detect Human Papillomavirus (HPV16) for Head and Neck Cancer.
Topics: Adenine; Carcinoma, Squamous Cell; Cell Line, Tumor; Chitosan; Chondroitin Sulfates; DNA, Single-Str | 2018 |
DNA repair gene polymorphisms and risk of head and neck cancer in the Tunisian population.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Arginine; Case-Control Studie | 2014 |
Association between cyclooxygenase-2 gene polymorphisms and head and neck squamous cell carcinoma risk.
Topics: 3' Untranslated Regions; Adenine; Adult; Aged; Alcohol Drinking; Carcinoma, Squamous Cell; Case-Cont | 2014 |
Transition state analogues in quorum sensing and SAM recycling.
Topics: Adenine; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; | 2008 |
BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Blotting, Western; Carcinoma, Squ | 2010 |
Hypermethylation of carcinogen metabolism genes, CYP1A1, CYP2A13 and GSTM1 genes in head and neck cancer.
Topics: Adenine; Alcohol Drinking; Aryl Hydrocarbon Hydroxylases; Carcinogens; Carcinoma, Squamous Cell; CpG | 2010 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
Topics: Adenine; DNA; Exons; Head and Neck Neoplasms; Humans; Melanocytes; Melanoma; Models, Genetic; Mutage | 2004 |
A case-control study investigating the role of sulfotransferase 1A1 polymorphism in head and neck cancer.
Topics: Adenine; Alleles; Arginine; Arylsulfotransferase; Carcinoma, Squamous Cell; Case-Control Studies; Co | 2006 |
Shorter CAG repeat length in the AR gene is associated with poor outcome in head and neck cancer.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Case-Control Studies; Cytosine; Diseas | 2007 |
Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer.
Topics: Adenine; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Alleles; Amino Acid Sequence; | 2001 |